Immucell Stock Price, News & Analysis

ImmuCell Corporation (Nasdaq: ICCC) plans to announce its unaudited financial results for Q2 2021 on August 12, 2021, after market close. A conference call to discuss these results is scheduled for August 13, 2021, at 9:00 AM ET. Investors will have access to the financial report via the company’s website post-release. ImmuCell focuses on developing products to enhance the health of dairy and beef cattle, including First Defense® for calf immunity and Re-Tain® for mastitis treatment.

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary unaudited sales results for Q2 2021, showing a 53% increase in product sales to approximately $4.5 million, compared to the same period last year. This follows a 10% increase in six-month sales to approximately $8.6 million. The company has nearly completed a $3.5 million investment to boost production capacity of its First Defense product, aiming for $30 million annual sales by Q3 2022. A backlog reduction was reported, with expectations of eliminating remaining orders by Q3 2021.

ImmuCell Corporation (Nasdaq: ICCC) announced that its 2021 Annual Meeting of Stockholders will be held virtually, scheduled for June 16, 2021, at 3:00 PM ET, due to COVID-19 precautions. Stockholders as of April 15, 2021, can participate via a live audio webcast or by telephone. Proxy voting is encouraged ahead of the meeting, with arrangements for those wishing to vote during the event. The company also encourages investors to review its recent Form 10-Q and Corporate Presentation for insights on its business and upcoming matters for vote.

ImmuCell Corporation (Nasdaq: ICCC) reported its Q1 2021 financial results with total product sales of $4.1 million, down 16% year-over-year. However, annual sales increased by 2% to $14.5 million. The company faced a backlog of $3.1 million, up from $1.8 million in Q4 2020. Gross margin declined to 39%, expected to return to 46% post-expansion. A $4.25 million equity raise was secured for growth initiatives. The net loss for Q1 2021 was $441,000, compared to a loss of $122,000 in Q1 2020. Cash reserves decreased to $6.8 million from $7.9 million.

ImmuCell Corporation (Nasdaq: ICCC) plans to release its unaudited financial results for Q1 2021 on May 13, 2021, after market close. A conference call will occur on May 14, 2021, at 9:00 AM ET to discuss these results and a recent equity raise. Investors can listen to the call via specified phone lines. Additionally, a Corporate Presentation will be available on the company's website following the earnings report. ImmuCell focuses on developing products to enhance the health of dairy and beef cattle.

ImmuCell Corporation (Nasdaq: ICCC) announced the closure of an equity investment on April 14, 2021, raising $4,250,037 by issuing 515,156 common shares at $8.25 each to its largest stockholder and other investors. The funds will facilitate growth initiatives, including increasing production capacity for First Defense® from $23 million to $30 million per year, conducting marketing studies, and expanding vaccine production. A conference call is scheduled for May 14, 2021, to discuss the investment and financial results.

ImmuCell Corporation (Nasdaq: ICCC) reported preliminary unaudited sales results for Q1 2021, revealing a 16% decline in total product sales, equating to a decrease of $791,000 compared to Q1 2020, totaling approximately $4.1 million. The decrease was anticipated due to higher beginning inventory last year. Despite this, the company noted a backlog of orders of approximately $3 million, indicating strong demand. Plans to increase annual production capacity from $16.5 million to $23 million are on schedule, expected to be completed by June 30, 2021.

ImmuCell Corporation (Nasdaq: ICCC) reported an increase in total product sales by $1.6 million, or 12%, to $15.3 million for the year ended December 31, 2020. The company submitted a crucial FDA filing for Re-Tain™, a mastitis product, with a response expected in Q3 2021. A backlog of orders worth $1.8 million was noted, attributed to COVID-19 disruptions. Gross margin decreased to 45% in 2020, attributed to higher fixed costs. Net loss improved to $1.022 million ($0.14 per share) compared to $1.296 million ($0.19 per share) in 2019. EBITDA increased to $1.893 million.

ImmuCell Corporation (Nasdaq: ICCC) will report unaudited financial results for the year ending December 31, 2020, on February 22, 2021. A conference call is scheduled for February 23, 2021, at 9:00 AM ET, to discuss the results. Interested parties can join by calling (844) 855-9502 (toll-free) or (412) 317-5499 (international). Following the call, a replay will be available for seven days. The company’s updated Corporate Presentation will be accessible on its website after the market closes on February 22, 2021, with the Annual Report on Form 10-K expected by March 30, 2021.